Previous close | 4.5000 |
Open | 3.5000 |
Bid | 1.6000 |
Ask | 5.9000 |
Strike | 290.00 |
Expiry date | 2024-06-21 |
Day's range | 3.3000 - 3.7000 |
Contract range | N/A |
Volume | |
Open interest | 285 |
Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.